Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15462038 | 0.94 | KMT2A (0.53) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL1618665 | 0.90 | ALDH1A1 (0.52) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL1619009 | 0.87 | WDR5 (0.52) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL1617562 | 0.87 | SLC6A9 (0.52) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL15462020 | 0.84 | LMNA (0.57) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL15462012 | 0.84 | ALDH1A1 (0.60) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL1618965 | 0.83 | ALDH1A1 (0.51) | KMT2ASMN1; SMN2ALDH1A1POLBMAPT | |
| SCHEMBL1619005 | 0.83 | SMN1; SMN2 (0.58) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL1619027 | 0.82 | ALDH1A1 (0.52) | KMT2ASMN1; SMN2ALDH1A1POLBPKM | |
| SCHEMBL1618982 | 0.82 | KMT2A (0.49) | KMT2ASMN1; SMN2ALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865720-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-21 | — | — | US | disclosed |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-06 | — | — | US | disclosed |
| US-8557825-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| US-20120088754-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF VAN (BE) | 2012-04-12 | — | — | US | disclosed |
| US-8097611-B2 | Sulfonyl-derivatives as novel or histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-01-17 | — | — | US | disclosed |
| US-20100240639-A1 | Sulfonyl-Derivatives as Novel or Histone Deacetylase | VAN EMELEN KRISTOF | 2010-09-23 | — | — | US | disclosed |
| US-7709487-B2 | anticancer agents; can be combined with other HDAC inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-04 | — | — | US | disclosed |
| US-7704998-B2 | anticancer agents; catalytic hydrogenation | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-27 | — | — | US | disclosed |
| US-20080108601-A1 | anticancer agents; catalytic hydrogenation | VAN EMELEN KRISTOF | 2008-05-08 | — | — | US | disclosed |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF V | 2007-06-21 | — | — | US | disclosed |
| US-7205304-B2 | medicine to inhibit proliferative conditions, such as cancer and psoriasis | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088754-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | KMT2A 28/4885MEN1 3455/4885SMN1; SMN2 3960/4885 |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | KMT2A 28/4885MEN1 3455/4885SMN1; SMN2 3960/4885 |
| US-20100240639-A1 | Sulfonyl-Derivatives as Novel or Histone Deacetylase | HDAC3, HDAC1, HDAC11 | KMT2A 36/4885MEN1 3328/4885SMN1; SMN2 3834/4885 |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | KMT2A 28/4885MEN1 3455/4885SMN1; SMN2 3960/4885 |
| US-20080108601-A1 | anticancer agents; catalytic hydrogenation | HDAC1, HDAC11, HDAC3 | KMT2A 50/4885MEN1 1475/4885SMN1; SMN2 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.